A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin - PubMed (original) (raw)
Meta-Analysis
doi: 10.2337/dc06-1789.
Affiliations
- PMID: 17259518
- DOI: 10.2337/dc06-1789
Meta-Analysis
A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin
Azim S Gangji et al. Diabetes Care. 2007 Feb.
Abstract
Objective: Glyburide is the most widely used sulfonylurea but has unique pharmacodynamic properties that may increase harm. We hypothesized that glyburide causes more hypoglycemia and cardiovascular events than other secretagogues or insulin.
Research design and methods: Data sources were Medline, Embase, Cochrane, and three other web-based clinical trial registers (1966-2005). Parallel, randomized, controlled trials in people with type 2 diabetes comparing glyburide monotherapy with monotherapy using secretagogues or insulin were selected. Outcomes were hypoglycemia, glycemic control, cardiovascular events, body weight, and death. Titles and abstracts of 1,806 publications were reviewed in duplicate and 21 relevant articles identified. Data on patient characteristics, interventions, outcomes, and validity were extracted in duplicate using predefined criteria.
Results: Glyburide was associated with a 52% greater risk of experiencing at least one episode of hypoglycemia compared with other secretagogues (relative risk 1.52 [95% CI 1.21-1.92]) and with 83% greater risk compared with other sulfonylureas (1.83 [1.35-2.49]). Glyburide was not associated with an increased risk of cardiovascular events (0.84 [0.56-1.26]), death (0.87 [0.70-1.07]), or end-of-trial weight (weighted mean difference 1.69 kg [95% CI -0.41 to 3.80]) compared with other secretagogues. Limitations included suboptimal reporting of original trials. Loss to follow-up exceeded 20% in some studies, and major hypoglycemia was infrequently reported.
Conclusions: Glyburide caused more hypoglycemia than other secretagogues and other sulfonylureas. Glyburide was not associated with an increased risk of cardiovascular events, death, or weight gain.
Similar articles
- Comparison of glyburide and insulin in the management of gestational diabetes: A meta-analysis.
Song R, Chen L, Chen Y, Si X, Liu Y, Liu Y, Irwin DM, Feng W. Song R, et al. PLoS One. 2017 Aug 3;12(8):e0182488. doi: 10.1371/journal.pone.0182488. eCollection 2017. PLoS One. 2017. PMID: 28771572 Free PMC article. - Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK, Yeh JI. Huang HK, et al. Diabetes Res Clin Pract. 2019 Jun;152:103-110. doi: 10.1016/j.diabres.2019.04.032. Epub 2019 May 18. Diabetes Res Clin Pract. 2019. PMID: 31108137 - Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes.
Moretti ME, Rezvani M, Koren G. Moretti ME, et al. Ann Pharmacother. 2008 Apr;42(4):483-90. doi: 10.1345/aph.1K577. Epub 2008 Mar 18. Ann Pharmacother. 2008. PMID: 18349305 - Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].
LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. LeBlanc EL, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. PMID: 30354042 Free Books & Documents. Review. - [Hypoglycemic risk of insulinotropic drugs].
Böhm R, Cascorbi I, Herdegen T. Böhm R, et al. Med Monatsschr Pharm. 2009 Dec;32(12):453-8. Med Monatsschr Pharm. 2009. PMID: 20088347 Review. German.
Cited by
- Effects of sitagliptin beyond glycemic control: focus on quality of life.
Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, Shimomura M, Taguchi I, Inoue T, Node K; S-DOG investigators. Sakamoto Y, et al. Cardiovasc Diabetol. 2013 Feb 21;12:35. doi: 10.1186/1475-2840-12-35. Cardiovasc Diabetol. 2013. PMID: 23432786 Free PMC article. - Diabetic cardiomyopathy.
Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, Heagerty AM, Malik RA. Asghar O, et al. Clin Sci (Lond). 2009 May;116(10):741-60. doi: 10.1042/CS20080500. Clin Sci (Lond). 2009. PMID: 19364331 Free PMC article. Review. - The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?
Pop LM, Lingvay I. Pop LM, et al. Curr Diab Rep. 2017 Oct 23;17(12):124. doi: 10.1007/s11892-017-0954-4. Curr Diab Rep. 2017. PMID: 29063276 Review. - Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE. Vos RC, et al. Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2. Cochrane Database Syst Rev. 2016. PMID: 27640062 Free PMC article. Review. - The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials.
Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitão C, Gross JL. Varvaki Rados D, et al. PLoS Med. 2016 Apr 12;13(4):e1001992. doi: 10.1371/journal.pmed.1001992. eCollection 2016 Apr. PLoS Med. 2016. PMID: 27071029 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical